Observational studyClinical rheumatology2026
Extension of cytokines' role in Behcet's disease associated peripheral neuropathy.
Observational study in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectiveBehçet's disease (BD) is a chronic multisystem inflammatory disorder with diverse neurological manifestations. While central nervous system involvement is well recognized, peripheral neuropathy remains an underdiagnosed and poorly understood complication. Chemokines, particularly C-C motif chemokine ligand 21 (CCL21), play a critical role in immune-mediated neuroinflammation and have been implicated in several autoimmune diseases. This study aimed to investigate the association between selected CCL21 gene polymorphisms and BD-associated peripheral neuropathy, and to assess their relationship with disease activity.
methodsThis cross-sectional observational study included 42 adult patients with BD and 20 age- and sex-matched healthy controls. All patients underwent comprehensive clinical and neurological evaluation, assessment of disease activity, and nerve conduction studies. Genotyping of CCL21 single nucleotide polymorphisms rs951005, rs2492358, and rs2812378 were performed for patients and controls.
resultsElectrophysiological evidence of peripheral neuropathy was detected in all evaluated Behçet's disease patients, despite only 50% reporting clinical neuropathic symptoms. Polyneuropathy was the predominant pattern, with sensory and mixed nerves more frequently affected than purely motor nerves, and greater involvement of upper limb nerves. A significant difference in the distribution of the CCL21 rs2492358 polymorphism was observed between patients and controls (p = 0.001). Additionally, the rs951005 polymorphism was significantly associated with higher disease activity scores (p = 0.009).
conclusionPeripheral neuropathy is a frequent and often subclinical manifestation of BD. CCL21 gene polymorphisms appear to contribute to both peripheral neuropathy association and disease activity, highlighting CCL21 as a potential biomarker linking systemic inflammation to peripheral nerve involvement. Key Points • Chemokine dysregulation previously found to play a central role in the development of neuroinflammation. • This cross-sectional study identifies specific chemokines' gene of CCL21 linked to peripheral neuropathy in Behcet's disease. • Results may guide future therapeutic strategies targeting chemokine modulation.
Indexed as
Identifiers
42397645What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.